Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UJ3C
|
|||
| Drug Name |
CD38-specific gene-engineered T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1/2 | [1] | |
| Company |
Shenzhen Geno-Immune Medical Institute
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclic ADP-ribose hydrolase 1 (CD38) | Target Info | CAR-T-Cell-Therapy | [1] |
| KEGG Pathway | Nicotinate and nicotinamide metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Oxytocin signaling pathway | ||||
| Salivary secretion | ||||
| Pancreatic secretion | ||||
| Epstein-Barr virus infection | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Panther Pathway | CCKR signaling map ST | |||
| WikiPathways | Oxytocin signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.